The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

TY - JOUR

T1 - The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

AU - Soedamah-Muthu, Sabita S.

AU - Charlton-Menys, Val

AU - Bao, Weihang

AU - Schalkwijk, Casper

AU - Stehouwer, Coen D. A.

AU - Colhoun, Helen M.

AU - Betteridge, D. John

AU - Durrington, Paul N.

AU - Hitman, Graham A.

AU - Neil, H. Andrew W.

AU - Livingstone, Shona J.

AU - Fuller, John H.

AU - DeMicco, David A.

AU - Preston, Gregory M.

N1 - Copyright 2012 Elsevier B.V., All rights reserved.

PY - 2011

Y1 - 2011

N2 - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD.

AB - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD.

UR - https://www.scopus.com/pages/publications/84855414845

U2 - 10.1177/1474651411425112

DO - 10.1177/1474651411425112

M3 - Article

AN - SCOPUS:84855414845

SN - 1474-6514

VL - 11

SP - 288

EP - 297

JO - The British Journal of Diabetes & Vascular Disease

JF - The British Journal of Diabetes & Vascular Disease

IS - 6

ER -